宜明昂科子公司---宜明凯尔IMC-015双抗专利正式递交差异化"减脂增肌"策略有望破局GLP-1肌肉流失痛点_老虎社区_美港股上老虎

宜明昂科子公司---宜明凯尔IMC-015双抗专利正式递交差异化"减脂增肌"策略有望破局GLP-1肌肉流失痛点

动脉网01-28

2026年1月28日，宜明昂科宣布子公司宜明凯尔自主研发的IMC-015双抗专利申请已递交，项目进入CMC和非临床研究阶段。肥胖是全球性健康问题，我国肥胖症患者众多，且肥胖会引发多种慢性病。GLP-1类药物虽减重效果显著，但会导致肌肉流失，维持肌肉质量是减肥重要挑战。IMC-015是宜明凯尔自主研发的双特异性抗体，能精准靶向调控肌肉生长抑制素信号通路，实现“减脂增肌”双重效应，体外研究显示其分子...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2606849796?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-28 14:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2606849796","market":"hk","top_or_hot":-1,"title":"宜明昂科子公司---宜明凯尔IMC-015双抗专利正式递交差异化\"减脂增肌\"策略有望破局GLP-1肌肉流失痛点","media":"动脉网","content":"<div>\n<p>2026年1月28日，宜明昂科宣布子公司宜明凯尔自主研发的IMC-015双抗专利申请已递交，项目进入CMC和非临床研究阶段。肥胖是全球性健康问题，我国肥胖症患者众多，且肥胖会引发多种慢性病。GLP-1类药物虽减重效果显著，但会导致肌肉流失，维持肌肉质量是减肥重要挑战。IMC-015是宜明凯尔自主研发的双特异性抗体，能精准靶向调控肌肉生长抑制素信号通路，实现“减脂增肌”双重效应，体外研究显示其分子...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128142827a6b609e7&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>宜明昂科子公司---宜明凯尔IMC-015双抗专利正式递交差异化\"减脂增肌\"策略有望破局GLP-1肌肉流失痛点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n宜明昂科子公司---宜明凯尔IMC-015双抗专利正式递交差异化\"减脂增肌\"策略有望破局GLP-1肌肉流失痛点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-28 14:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128142827a6b609e7&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2026年1月28日，宜明昂科宣布子公司宜明凯尔自主研发的IMC-015双抗专利申请已递交，项目进入CMC和非临床研究阶段。肥胖是全球性健康问题，我国肥胖症患者众多，且肥胖会引发多种慢性病。GLP-1类药物虽减重效果显著，但会导致肌肉流失，维持肌肉质量是减肥重要挑战。IMC-015是宜明凯尔自主研发的双特异性抗体，能精准靶向调控肌肉生长抑制素信号通路，实现“减脂增肌”双重效应，体外研究显示其分子...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128142827a6b609e7&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128142827a6b609e7&s=b","article_id":"2606849796","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128142827a6b609e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606849796","pubTimestamp":1769580660,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2026年1月28日，宜明昂科宣布子公司宜明凯尔自主研发的IMC-015双抗专利申请已递交，项目进入CMC和非临床研究阶段。肥胖是全球性健康问题，我国肥胖症患者众多，且肥胖会引发多种慢性病。GLP-1类药物虽减重效果显著，但会导致肌肉流失，维持肌肉质量是减肥重要挑战。IMC-015是宜明凯尔自主研发的双特异性抗体，能精准靶向调控肌肉生长抑制素信号通路，实现“减脂增肌”双重效应，体外研究显示其分子活性更优，与Bimagrumab相比，肌肉组织特异性提升，预期安全性更优。在肥胖小鼠模型中，IMC-015与司美格鲁肽联用增肌减脂药效明显优于同类药物，验证了其在GLP-1联合治疗中的潜力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01541":"宜明昂科-B","BK1161":"生物科技"},"translate_title":"Yiming Angke's subsidiary---Yiming Kaier IMC-015 dual antibody patent officially submitted. The differentiated \"fat loss and muscle gain\" strategy is expected to break the pain point of GLP-1 muscle loss","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":0.9},"content_text":"2026年1月28日，宜明昂科宣布子公司宜明凯尔自主研发的IMC-015双抗专利申请已递交，项目进入CMC和非临床研究阶段。肥胖是全球性健康问题，我国肥胖症患者众多，且肥胖会引发多种慢性病。GLP-1类药物虽减重效果显著，但会导致肌肉流失，维持肌肉质量是减肥重要挑战。IMC-015是宜明凯尔自主研发的双特异性抗体，能精准靶向调控肌肉生长抑制素信号通路，实现“减脂增肌”双重效应，体外研究显示其分子活性更优，与Bimagrumab相比，肌肉组织特异性提升，预期安全性更优。在肥胖小鼠模型中，IMC-015与司美格鲁肽联用增肌减脂药效明显优于同类药物，验证了其在GLP-1联合治疗中的潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}